Currently, we plan to use AS1842856 administered via intraperitoneal injection to intervene in the FOXO1 pathway in a rat model of coronary heart disease.
In SD rat experiments, can AS1842856 (HY-100596, MCE) be administered via intraperitoneal injection?
If the rat weighs 500g, what is your recommended dosage (mg/kg/day) to effectively inhibit FOXO1 expression? Is it necessary to administer the injection in divided doses (e.g., once or twice daily)?